Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2 Inhibitor Effect on Cellular Senescence in T2D
NCT05975528Phase 4Recruiting
- Sponsor
- Yonsei University
- Start
- Jun 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of empagliflozin, dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Yonsei University. Started Jun 2023; status: recruiting.
02
Drugs
empagliflozindapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05975528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05975528.